CIndU Care: Antihistamine Up-Titration Anchors a Still-Gappy Algorithm
CIndU management still hinges on up-titrating H1-antihistamines up to fourfold, but experts flag thin subtype-specific evidence and a sparse pipeline beyond omalizumab.
Topic
Omalizumab
Topic
Omalizumab
Why Second-Generation H1 Antihistamines Fall Short in CIndU
Second-generation H1 antihistamines leave many chronic inducible urticaria patients uncontrolled, Dermatology Times review finds.
Omalizumab Drug Survival Reaches 3.1 Years in Chronic Urticaria
A JAMA Dermatology meta-analysis of 4,516 patients found median omalizumab drug survival of 3.1 years in chronic urticaria, with…